Effect of Initial Aflibercept, Laser, or Observation on Low-Contrast Visual Acuity in Eyes With Diabetic Macular Edema and Good Vision: Ancillary Study Within a Randomized Clinical Trial

被引:5
|
作者
Beaulieu, Wesley T. [1 ]
Glassman, Adam R. [1 ]
Baker, Carl W. [2 ]
Maguire, Maureen G. [3 ]
Johnson, Chris A. [4 ]
Melia, Michele [1 ]
Sun, Jennifer K. [5 ]
机构
[1] Jaeb Ctr Hlth Res, 15310 Amberly Dr,Suite 350, Tampa, FL 33647 USA
[2] Paducah Retinal Ctr, Paducah, KY USA
[3] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA
[4] Univ Iowa, Dept Ophthalmol & Visual Sci, Iowa City, IA USA
[5] Harvard Dept Ophthalmol, Beetham Eye Inst, Joslin Diabet Ctr, Boston, MA USA
来源
TRANSLATIONAL VISION SCIENCE & TECHNOLOGY | 2021年 / 10卷 / 03期
基金
美国国家卫生研究院;
关键词
low-contrast; visual acuity; DME; Protocol V; OUTCOME MEASURE; SENSITIVITY; RETINOPATHY; PERFORMANCE; VALIDATION; VALIDITY; TESTS; RISK; LIFE;
D O I
10.1167/tvst.10.3.3
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To describe 2.5% low-contrast visual acuity (VA) among eyes with good vision despite center-involved diabetic macular edema and compare changes after initial management with aflibercept, laser, or observation. Methods: This was an ancillary study within a multicenter randomized clinical trial (DRCR Retina Network Protocol V). Participants had diabetes and 1 study eye with center-involved diabetic macular edema and a VA of 20/25 or better randomly assigned to aflibercept (n = 112), focal/grid laser (n = 146), or observation (n = 129). Eyes in the laser and observation groups received aflibercept if VA met prespecified worsening criteria. Results: Participants had median age of 60 years, 37% were female and 70% were non-Hispanic White. At baseline, the mean +/- standard deviation (SD) high-contrast VA was 85.2 +/- 3.6 letters (Snellen equivalent 20/20), mean +/- SD 2.5% low-contrast VA was 47.6 +/- 18.9 letters (Snellen equivalent 20/125), and low-contrast VA letter score was 2 SDs or more below the age-specific normative values in 23%. At 2 years, the mean change +/- SD in low-contrast VA in the aflibercept, laser, and observation groups was 2.7 +/- 20.1, -2.0 +/- 19.6, and -3.1 +/- 20.8 letters (adjusted difference, aflibercept vs. laser, 5.3 [95% confidence interval, -0.2 to 10.8], P = 0.06; aflibercept vs. observation, 5.5 [95% confidence interval -0.2 to 11.2], P= 0.06; and laser vs. observation, 0.2 [95% confidence interval -4.6 to 5.0], P = 0.94). Conclusions: There was no significant difference between treatment groups in low-contrast VA change from baseline to 2 years. Considering the range of the 95% confidence intervals, however, the study may have been underpowered to detect a clinically meaningful benefit between treatment groups. Translational Relevance: Low-contrast VA, an important visual function, is decreased in eyes with diabetic macular edema.
引用
收藏
页码:1 / 12
页数:12
相关论文
共 16 条
  • [1] Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity A Randomized Clinical Trial
    Baker, Carl W.
    Glassman, Adam R.
    Beaulieu, Wesley T.
    Antoszyk, Andrew N.
    Browning, David J.
    Chalam, Kakarla V.
    Grover, Sandeep
    Jampol, Lee M.
    Jhaveri, Chirag D.
    Melia, Michele
    Stockdale, Cynthia R.
    Martin, Daniel F.
    Sun, Jennifer K.
    Allen, John Bradley
    Punjabi, Omar S.
    Price, Angela K.
    Jones, Taylor S.
    Mahr, Courtney
    Herby, Jenna T.
    Murphy, Brittany A.
    McClain, Ashley A.
    Fredenberg, Sherry L.
    Fleming, Christina J.
    Lester, Gina M.
    Karow, Angella S.
    Breglio, Erica
    Grupp, Autumn C.
    Ennis, Sarah A.
    Bratcher, Kayla A.
    Watson, Lynn
    Bojaj, Swann J.
    McClain, Donna
    Finch, Autumn K.
    Dunlap, Matt
    McOwen, Michael D.
    Stobbe, Shannon
    Rowland, Beverly O.
    Jackson, Lisa A.
    Clark, Loraine M.
    Balasubramaniam, Uma M.
    Kimrey, Kathryn
    Ragin, Teneisha A.
    Held, Susannah J.
    Kuopus, Jeff A.
    Shore, Carol A.
    Wykoff, Charles C.
    Kim, Rosa Y.
    Shah, Ankoor R.
    Schefler, Amy C.
    Wong, Tien P.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 321 (19): : 1880 - 1894
  • [2] Subthreshold Micropulse Laser for Eyes With Center Involving Diabetic Macular Edema With Good Visual Acuity: The PULSE Study, a Randomized Clinical Trial
    Feldman, Samuel
    Basra, Jesse
    Lawani, Anjola
    Ren, Yunyi
    Wilson, Machelle
    Moshiri, Ala
    Park, Susanna S.
    Yiu, Glenn
    OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2025, 56 (02) : 86 - 93
  • [3] Costs of Managing Diabetic Macular Edema With Good Visual Acuity With Aflibercept, Laser, or Observation: DRCR Retina Network Protocol V
    Hutton, David W.
    Glassman, Adam R.
    Stein, Joshua D.
    Bressler, Neil M.
    Sun, Jennifer K.
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2021, 230 : 297 - 302
  • [4] Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity A Secondary Analysis of a Randomized Clinical Trial
    Glassman, Adam R.
    Baker, Carl W.
    Beaulieu, Wesley T.
    Bressler, Neil M.
    Punjabi, Omar S.
    Stockdale, Cynthia R.
    Wykoff, Charles C.
    Jampol, Lee M.
    Sun, Jennifer K.
    JAMA OPHTHALMOLOGY, 2020, 138 (04) : 341 - 349
  • [5] Randomized clinical trial comparing intravitreal aflibercept combined with subthreshold laser to intravitreal aflibercept monotherapy for diabetic macular edema
    Tatsumi, Tomoaki
    Takatsuna, Yoko
    Oshitari, Toshiyuki
    Kaiho, Tomomi
    Kawasaki, Yohei
    Shiko, Yuki
    Sugawara, Takeshi
    Baba, Takayuki
    Yamamoto, Shuichi
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [6] Aflibercept plus micropulse laser versus aflibercept monotherapy for diabetic macular edema: 1-year results of a randomized clinical trial
    Abouhussein, Mahmoud Alaa
    Gomaa, Amir Ramadan
    INTERNATIONAL OPHTHALMOLOGY, 2020, 40 (05) : 1147 - 1154
  • [7] Real-world outcomes of observation and treatment in diabetic macular edema with very good visual acuity: the OBTAIN study
    Busch, Catharina
    Fraser-Bell, Samantha
    Zur, Dinah
    Rodriguez-Valdes, Patricio J.
    Cebeci, Zafer
    Lupidi, Marco
    Fung, Adrian T.
    Gabrielle, Pierre-Henry
    Giancipoli, Ermete
    Chaikitmongkol, Voraporn
    Okada, Mali
    Lains, Ines
    Santos, Ana Rita
    Kunavisarut, Paradee
    Sala-Puigdollers, Anna
    Chhablani, Jay
    Ozimek, Malgorzata
    Hilely, Assaf
    Unterlauft, Jan Darius
    Loewenstein, Anat
    Iglicki, Matias
    Rehak, Matus
    ACTA DIABETOLOGICA, 2019, 56 (07) : 777 - 784
  • [8] Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment A Secondary Analysis of a Randomized Clinical Trial
    Bressler, Neil M.
    Beaulieu, Wesley T.
    Glassman, Adam R.
    Blinder, Kevin J.
    Bressler, Susan B.
    Jampol, Lee M.
    Melia, Michele
    Wells, John A., III
    JAMA OPHTHALMOLOGY, 2018, 136 (03) : 257 - 269
  • [9] ASSOCIATION OF FLUORESCEIN ANGIOGRAPHIC FEATURES WITH VISUAL ACUITY AND WITH OPTICAL COHERENCE TOMOGRAPHIC AND STEREOSCOPIC COLOR FUNDUS PHOTOGRAPHIC FEATURES OF DIABETIC MACULAR EDEMA IN A RANDOMIZED CLINICAL TRIAL
    Danis, Ronald P.
    Scott, Ingrid U.
    Qin, Haijing
    Altaweel, Michael M.
    Bressler, Neil M.
    Bressler, Susan B.
    Browning, David J.
    Kollman, Craig
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2010, 30 (10): : 1627 - 1637
  • [10] Association Between Change in Visual Acuity and Change in Central Subfield Thickness During Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept, Bevacizumab, or Ranibizumab: A Post Hoc Analysis of the Protocol T Randomized Clinical Trial
    Bressler, Neil M.
    Odia, Isoken
    Maguire, Maureen
    Glassman, Adam R.
    Jampol, Lee M.
    MacCumber, Mathew W.
    Shah, Chirag
    Rosberger, Daniel
    Sun, Jennifer K.
    Brown, Justin C.
    Antoszyk, Andrew N.
    Browning, David
    Price, Angela K.
    Fredenberg, Sherry L.
    Herby, Jenna T.
    Walker, Merri F.
    Fleming, Christina J.
    McClain, Ashley A.
    Karow, Angella S.
    Grupp, Autumn C.
    Gallagher, Kelly R.
    Ennis, Sarah A.
    McClain, Donna
    Mondelb, Joan P.
    Finch, Autumn K.
    Kimrey, Kathryn
    Clark, Loraine M.
    Jackson, Lisa A.
    Watson, Lynn
    Kuopus, Jeff A.
    Kerr, Robin
    Bojaj, Swann J.
    Held, Susannah J.
    Balasubramaniam, Uma M.
    McOwen, Michael D.
    Dunlap, Matt
    Elman, Michael J.
    Leder, Henry A.
    Starr, JoAnn
    Belz, Jennifer L.
    Putzulo, Charlene K.
    Salfer-Firestone, Dena Y.
    Simpson, Perel M.
    Singletary, Pamela, V
    Simmons, Jennifer L.
    Coffey, Teresa
    Sandler, Dallas R.
    Davis, Ashley
    Metzger, Ashley M.
    Sotirakos, Peter
    JAMA OPHTHALMOLOGY, 2019, 137 (09) : 977 - 985